Non-Small Cell Lung Cancer

3,228 clinical trials · Condition

Record	Firm	Date
Fluorine-18-α-Methyltyrosine Positron Emission Tomography (18F-FMT PET) for Therapy Response in Lung Cancer (NCT00826033)	Gunma University
Electromagnetic Navigational Bronchoscopy Vs. Transthoracic Needle Biopsy for the Sampling of Peripheral Lung Nodules (NCT02651506)	St. Joseph's Healthcare Hamilton
Rociletinib (CO-1686) USA Expanded Access Program (NCT02547675)	Clovis Oncology, Inc.
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor (NCT04100694)	Merus B.V.
Random Trial for Elderly Patients With NSCLC (NCT00265694)	Inje University
Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors (NCT01449357)	Genmab
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors (NCT06797362)	Nuvalent Inc.
Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer (NCT00050973)	Eisai Inc.
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies (NCT04566393)	xCures
Evaluating Efficacy and Safety of Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Chemotherapy (NCT01297101)	Shanghai Chest Hospital
An EAP Treatment Protocol of Zipalertinib (NCT07601399)	Taiho Oncology, Inc.
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck (NCT00684385)	AstraZeneca
Expanded Access to Ensartinib for Participants With ALK+ NSCLC (NCT04146571)	Xcovery Holdings, Inc.
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC (NCT04204928)	Blueprint Medicines Corporation
Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer (NCT00099879)	Bristol-Myers Squibb
Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer (NCT00103831)	Bristol-Myers Squibb

Track Non-Small Cell Lung Cancer automatically

Every clearance here is in the API, with alerts when new ones post.